{"product_id":"santen-ansoff-matrix","title":"Santen Pharmaceutical Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Santen Pharmaceutical Amsoff Matrix Analysis gives a clear view of the company’s growth options across market penetration, market development, product development, and diversification. This page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaucoma share defense in Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanten Pharmaceutical defends its Japan glaucoma franchise by leaning on Eybelis and other long-use brands, where refill persistence matters as much as new starts. Japan’s 65+ population was 29.3% in 2024, so the chronic glaucoma pool stays large and specialist-led. Hospital ties, clinician education, and switch prevention protect share in a market where one lost refill can cut lifetime value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDry-eye repeat prescribing with Diquas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiquas fits repeat prescribing because dry-eye care is long term, not one-off, and patients often stay on therapy for months. In 2025, Santen Pharmaceutical kept this drug embedded in routine ophthalmology use, which helps defend market share where physicians prefer familiar, well-tolerated brands. The market is large and chronic, so even small gains in refill retention can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllergy season demand from Alesion and OTC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, allergic conjunctivitis still drives a repeat spring buy cycle in Japan, where cedar pollen season hits every year and keeps branded eye drops top of mind. Santen Pharmaceutical can use Alesion and OTC ranges to catch both prescription and store traffic as symptoms flare. This is strong market penetration because the same patients often repurchase each allergy season.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreservative-free formats strengthen adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePreservative-free and single-use eye-drop formats help Santen Pharmaceutical defend share in chronic therapy areas where patients may use treatment for years, not weeks. In ophthalmology, tolerability drives persistence, and better comfort can cut discontinuation versus older preserved drops. That matters for market penetration because longer use supports repeat prescribing and longer brand life.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist-led selling protects premium brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn FY2025, Santen Pharmaceutical Co., Ltd. reported net sales of about JPY 300 billion, and that scale still depends on specialist-led eye care. Ophthalmology stays clinic and hospital based, so Santen Pharmaceutical Co., Ltd. uses eye doctors to defend premium products from generic and local rivals. In Japan, where clinical trust drives repeat prescribing, that channel mix helps protect pricing and patient loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanten’s Repeat-Care Engine Keeps Japan Sales Near JPY 300 Billion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Santen Pharmaceutical Co., Ltd. used repeat care in Japan to defend share, with net sales about JPY 300 billion. Eybelis, Diquas, and Alesion fit chronic glaucoma, dry-eye, and seasonal allergy use, where refill persistence drives revenue. Japan’s 65+ population was 29.3% in 2024, so the treated pool stays large.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003eJPY 300 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan age 65+ share\u003c\/td\u003e\n\u003ctd\u003e29.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore penetration lever\u003c\/td\u003e\n\u003ctd\u003eRepeat prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Amsoff Matrix framework for analyzing Santen Pharmaceutical’s growth strategy across products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear, at-a-glance Ansoff Matrix for Santen Pharmaceutical to quickly identify growth options and ease strategic planning pain points.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRyjunea expands into European markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRyjunea is Santen Pharmaceutical’s clearest market-development move: it uses an existing ophthalmology asset in a new geography. The product, approved in the EU in 2024, targets myopia progression in children aged 3 to 14, opening a large non-Japan growth lane. It is a classic Ansoff fit: same core expertise, new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e60-plus country footprint supports rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanten Pharmaceutical's presence in more than 60 countries and regions makes market development a rollout job, not a startup build. Existing eye-care products can be added country by country as local approvals and reimbursement clear, so each launch uses the same core asset base. That lowers execution risk and helps capital stay focused on registrations, pricing, and distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina and Asia remain key growth lanes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChina and Southeast Asia stay key growth lanes for Santen Pharmaceutical because aging and myopia keep lifting ophthalmology demand. China had more than 300 million people aged 60+ in 2024, and high myopia rates across Asia keep the addressable patient pool large. Santen can push the same core eye-care products into nearby markets with similar medical needs, so it scales without leaving specialty eye care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led entry lowers fixed cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePartner-led licensing and distribution let Santen Pharmaceutical enter new markets without a full sales build-out, so fixed costs stay low. That matters in ophthalmology, where country-by-country approvals and local launch rules can stretch timelines and raise spend; one partner can cover multiple steps. This setup also keeps more capital for R\u0026amp;D and launch support, which is key after FY2025-era price and regulatory pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSequential filings reduce launch risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanten Pharmaceutical’s country-by-country filings lower launch risk because each market is cleared on its own regulatory and reimbursement timeline, instead of betting on a single wide rollout. That slower path fits pharma, where approval, pricing, and payer review can stretch launch timing by months and vary sharply by country. It also helps Santen Pharmaceutical focus 2025 and 2026 on the markets with the best odds of approval and reimbursement, which makes the sales forecast cleaner and the capital plan easier to control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanten’s low-cost global rollout taps rising myopia demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanten Pharmaceutical’s market development is a low-cost rollout of existing eye-care assets into new countries. Ryjunea, approved in the EU in 2024, extends myopia treatment to children aged 3-14 and fits this new-market play.\u003c\/p\u003e\n\u003cp\u003eIts reach in 60+ countries and regions lets it add launches country by country as approvals and reimbursement land. China’s 300m+ people aged 60+ in 2024 and Asia’s high myopia rates keep demand strong.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025-relevant fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeography\u003c\/td\u003e\n\u003ctd\u003e60+ countries and regions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRyjunea\u003c\/td\u003e\n\u003ctd\u003eEU approval in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina aging\u003c\/td\u003e\n\u003ctd\u003e300m+ aged 60+ in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSanten Pharmaceutical Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Santen Pharmaceutical Amsoff Matrix analysis document you’ll receive upon purchase—no surprises, just the full professional version. The preview below is taken directly from the complete report, so what you see is exactly what you get. Unlock the entire in-depth Amsoff Matrix analysis after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRyjunea adds a pediatric myopia product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRyjunea is a major product-development step for Santen Pharmaceutical because it adds 1 new branded treatment for pediatric myopia progression, a segment covering children ages 3 to 14. \u003c\/p\u003e\n\u003cp\u003eThis moves Santen Pharmaceutical beyond adult chronic care and into prevention-focused eye care, which can widen the portfolio and support longer-term revenue growth. \u003c\/p\u003e\n\u003cp\u003eIn Amsoff Matrix terms, this is product development: 1 existing company entering a new pediatric use case with a targeted therapy. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmidenepag refreshes the glaucoma franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmidenepag isopropyl, sold as Eybelis in Japan, is Santen Pharmaceutical’s push into next-generation glaucoma care. Its EP2 receptor agonist mechanism can help it compete on efficacy and tolerability versus older eye drops, which matters because glaucoma often needs years of daily treatment. Santen Pharmaceutical reported net sales of ¥300.8 billion in fiscal 2025, and products like Eybelis help refresh the franchise by aiming to improve adherence in a chronic, high-burden market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormulation science extends product life\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanten Pharmaceutical can extend existing molecules into new branded assets by improving delivery, tolerability, or convenience, which fits Ansoff’s product development path with lower risk than a new molecule launch. Preservative-free, easy-to-use ophthalmic formats matter because many chronic users need daily, long-term treatment and comfort drives adherence. In FY2025, that kind of reformulation can support value capture without starting from zero.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDry-eye innovation keeps the pipeline relevant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDry-eye disease is a huge chronic market, with about 344 million people affected worldwide, so Santen Pharmaceutical has room to keep improving ocular-surface therapies. The real win is not only faster symptom relief, but longer control and better patient persistence, which matters in a disease that often needs repeat treatment. That supports steady, low-risk product upgrades and line extensions. In FY2025, that kind of pipeline fit still matters because chronic eye care rewards recurring use and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric dosing broadens the innovation base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePediatric dosing broadens Santen Pharmaceutical's innovation base because children need tighter safety, dose, and usability design than adults, so a simple adult-line extension won’t do. With myopia affecting about 2.6 billion people worldwide and early treatment now seen as a multi-year play, Santen Pharmaceutical can build products with longer clinical use and stronger switching costs.\u003c\/p\u003e\n\u003cp\u003eThat makes the pipeline more defensible, since pediatric standards raise development barriers and support higher-value, specialized products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanten’s FY2025 eye-care product push drives ¥300.8B sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Santen Pharmaceutical’s product development focused on new eye-care uses for existing strengths, led by Ryjunea for pediatric myopia and Eybelis for glaucoma. This fits Ansoff product development: new products for related patient needs, not a new business. FY2025 net sales were ¥300.8 billion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e¥300.8 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRyjunea use\u003c\/td\u003e\n\u003ctd\u003ePediatric myopia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEybelis use\u003c\/td\u003e\n\u003ctd\u003eGlaucoma care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTC eye care adds consumer exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanten Pharmaceutical's OTC eye care line adds consumer exposure beyond prescription drugs, so revenue is tied not just to clinics but also to shopping habits in eye comfort, allergy relief, and daily care. That is adjacent diversification: it does not leave eye health, but it broadens the business model into consumer demand and repeat purchases. In FY2025, this kind of mix matters because OTC products can soften dependence on Rx volumes and add a more stable retail channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical devices widen the portfolio mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical devices give Santen Pharmaceutical a non-drug revenue stream inside ophthalmology, so FY2025 exposure is less tied to one drug class. That mix can deepen ties with eye-care professionals, because devices and prescription medicines are often used together in patient care. It also broadens the portfolio beyond patents and pricing pressure on a single therapy line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal mix reduces single-market exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanten Pharmaceutical uses a broad geographic and product mix, so one reimbursement change or one regulator’s delay does not hit all revenue at once. That is a real portfolio hedge for a specialty pharma firm because eye-care demand can shift by market and by therapy line. By staying in multiple countries while keeping its core ophthalmology focus, Santen Pharmaceutical spreads risk without stepping outside its expertise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyopia expands the disease mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMoving into pediatric myopia widens Santen Pharmaceutical’s eye-care mix beyond glaucoma, dry eye, and allergy, shifting it from upkeep toward prevention-led growth. This matters in a market where myopia affects about 2.6 billion people worldwide and is projected to reach 3.3 billion by 2030, so even a small pediatric share can add durable demand.\u003c\/p\u003e\n\u003cp\u003eThat broader disease spread can lift brand relevance over time and reduce reliance on mature treatment lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjacent moves beat unrelated expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanten Pharmaceutical favors adjacent diversification over unrelated expansion, and that fits its 2025 FY eye care base. Commercialization, medical affairs, and manufacturing all transfer well across ophthalmology, so new products can reuse the same field force, regulatory know-how, and production assets.\u003c\/p\u003e\n\u003cp\u003eThis gives Santen Pharmaceutical growth optionality without the higher failure risk of a new sector. One line: move next door, not across the street.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanten Expands Beyond Rx with Adjacent Ophthalmology Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Santen Pharmaceutical’s diversification stayed adjacent: OTC eye care, devices, pediatric myopia, and wider geography all sit inside ophthalmology. That reduces reliance on one Rx line and one payer channel. With myopia affecting about 2.6 billion people and forecast at 3.3 billion by 2030, the pediatric mix adds a bigger long-run pool.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eFY2025 role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC\u003c\/td\u003e\n\u003ctd\u003eConsumer demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices\u003c\/td\u003e\n\u003ctd\u003eNon-drug revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyopia\u003c\/td\u003e\n\u003ctd\u003eGrowth driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeography\u003c\/td\u003e\n\u003ctd\u003eRisk spread\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53650484724054,"sku":"santen-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/santen-ansoff-analysis.webp?v=1778897222","url":"https:\/\/balancedscorecardexamples.com\/products\/santen-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}